Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LIBREXIA-AF: Milvexian vs Apixaban in Atrial Fibrillation
jRCT2051230052Phase 3Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Jul 2023
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of milvexian in Atrial fibrillation (AFib) (2 arms), sponsored by Janssen Pharmaceutical. Started Jul 2023; status: active, not recruiting.
02
Drugs
milvexian
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on jRCT2051230052.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051230052.